Holocene Advisors LP Boosts Holdings in Exact Sciences Corporation $EXAS

Holocene Advisors LP grew its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 27.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,725,390 shares of the medical research company’s stock after purchasing an additional 580,209 shares during the period. Holocene Advisors LP’s holdings in Exact Sciences were worth $149,106,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of EXAS. Comerica Bank raised its stake in Exact Sciences by 9.2% in the third quarter. Comerica Bank now owns 1,954 shares of the medical research company’s stock worth $107,000 after buying an additional 164 shares in the last quarter. Great Lakes Advisors LLC boosted its position in Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after acquiring an additional 178 shares in the last quarter. Capital Asset Advisory Services LLC grew its holdings in shares of Exact Sciences by 4.8% during the 3rd quarter. Capital Asset Advisory Services LLC now owns 3,941 shares of the medical research company’s stock worth $216,000 after acquiring an additional 182 shares during the period. Assetmark Inc. grew its holdings in shares of Exact Sciences by 7.2% during the 3rd quarter. Assetmark Inc. now owns 3,588 shares of the medical research company’s stock worth $196,000 after acquiring an additional 242 shares during the period. Finally, Westside Investment Management Inc. raised its position in shares of Exact Sciences by 100.0% in the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after acquiring an additional 271 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Robert W. Baird set a $105.00 price target on Exact Sciences in a research report on Thursday, November 20th. Wells Fargo & Company reissued an “equal weight” rating and set a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research report on Thursday, November 20th. TD Cowen lowered Exact Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Guggenheim cut shares of Exact Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 20th. Finally, Zacks Research downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Twenty-one equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $92.13.

Exact Sciences Stock Up 0.3%

EXAS stock opened at $103.57 on Monday. Exact Sciences Corporation has a twelve month low of $38.81 and a twelve month high of $103.75. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97. The firm has a market cap of $19.77 billion, a PE ratio of -94.15, a price-to-earnings-growth ratio of 2.36 and a beta of 1.41. The business has a 50 day moving average of $102.83 and a 200 day moving average of $84.12.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same period in the prior year, the company earned ($0.06) earnings per share. The firm’s revenue was up 23.1% on a year-over-year basis. On average, research analysts forecast that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.